The mechanistic bridge between inflammatory bowel disease and cancer risk has remained elusive despite decades of clinical observation. This finding matters because it could transform how we monitor and treat the 900,000 Americans living with ulcerative colitis, many unaware of their elevated cancer susceptibility. Advanced genomic mapping across over 112,000 patients reveals that CD4+ T cells function as the central immune orchestrator in ulcerative colitis, driving a cascade of metabolic reprogramming through the Th17/IL-17 inflammatory pathway and altered cellular energy production. The analysis pinpointed the terminal ileum and transverse colon as genetic vulnerability zones, with disease susceptibility programs traceable to embryonic gut development at 16.5 weeks gestation. Five priority genes emerged as potential therapeutic targets: ARPC5, PTGER4, CIB1, PREX1, and S100A10, each playing distinct roles in the inflammatory-to-malignant transition. The research demonstrates how chronic inflammatory stress systematically dismantles cellular quality control mechanisms, particularly p53 tumor suppression pathways, while simultaneously triggering epithelial-mesenchymal transition that enables cancer cell mobility and blood vessel remodeling. This represents a significant advance in precision medicine for inflammatory bowel diseases. Unlike previous studies that examined inflammation and cancer separately, this work maps the complete molecular trajectory from initial immune dysfunction to malignant transformation. The single-cell resolution provides unprecedented detail about which specific cell populations drive disease progression, potentially enabling targeted interventions before cancer develops. However, translation to clinical practice will require validation studies and development of practical screening protocols that can identify high-risk patients early in their disease course.